Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HTR1B | P28222 | 4/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | RGS12 | O14924 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30427252 | 1.00 | GAA (0.49) | GAAMEN1ALDH1A1KMT2AHTR1B | |
| SCHEMBL103859 | 0.86 | GAA (0.53) | GAAMEN1ALDH1A1KMT2AHTR1B | |
| SCHEMBL5985385 | 0.84 | HTR1B (0.50) | HTR1BPTGS1AKR1C3AKR1C2KDM4E | |
| SCHEMBL30426935 | 0.84 | HTR1B (0.50) | HTR1BPTGS1AKR1C3AKR1C2KDM4E | |
| SCHEMBL11195944 | 0.84 | HTR1B (0.46) | GAAMEN1ALDH1A1KMT2AHTR1B | |
| SCHEMBL24111926 | 0.81 | HTR1B (0.49) | GAAHTR1BKDM4EHSD17B10NFKB1 | |
| SCHEMBL23804837 | 0.80 | CYP1A2 (0.58) | HTR1BMAPTHSD17B10CHRM2CHRM1 | |
| SCHEMBL2095530 | 0.80 | HTR1B (0.53) | HTR1BKDM4EHSD17B10NFKB1CHRM2 | |
| SCHEMBL25477856 | 0.79 | HTR1B (0.47) | HTR1BKDM4EHSD17B10NFKB1CHRM2 | |
| SCHEMBL24111713 | 0.79 | HTR1B (0.42) | HTR1BKDM4EHSD17B10NFKB1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404257-B2 | Advantageous benzofuran compositions for mental disorders or enhancement | TACTOGEN INC (US) | 2025-09-02 | — | — | US | disclosed |
| US-12365661-B2 | Advantageous benzofuran compositions for mental disorders or enhancement | TACTOGEN INC (US) | 2025-07-22 | — | — | US | disclosed |
| US-12344591-B2 | Advantageous benzofuran compositions for mental disorders or enhancement | TACTOGEN INC (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250188049-A1 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2025-06-12 | — | — | US | disclosed |
| US-20250034102-A1 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2025-01-30 | — | — | US | disclosed |
| US-20250019357-A1 | BENZOFURAN SALT MORPHIC FORMS AND MIXTURES FOR THE TREATMENT OF MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2025-01-16 | — | — | US | disclosed |
| EP-4444283-A1 | SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | Tactogen Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-4444296-A2 | BENZOFURAN SALT MORPHIC FORMS AND MIXTURES FOR THE TREATMENT OF MENTAL DISORDERS OR MENTAL ENHANCEMENT | Tactogen Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| US-20240083864-A1 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC | 2024-03-14 | — | — | US | disclosed |
| US-11767305-B2 | Advantageous benzofuran compositions for mental disorders or enhancement | TACTOGEN INC (US) | 2023-09-26 | — | — | US | disclosed |
| WO-2011044394-A1 | PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-04-14 | — | — | WO | disclosed |
| US-6689797-B2 | TUMOUR NECROSIS FACTOR MODULATORS | SANOFI-SYNTHELABO (FR) | 2004-02-10 | — | — | US | disclosed |
| US-20030083347-A1 | Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2003-05-01 | — | — | US | disclosed |
| EP-0646112-A4 | TERTIARY AND SECONDARY AMINES AS ALPHA-2 ANTAGONISTS AND SEROTONIN UPTAKE INHIBITORS. | ABBOTT LAB (US) | 1997-04-02 | — | — | EP | disclosed |
| EP-0646112-A1 | TERTIARY AND SECONDARY AMINES AS ALPHA-2 ANTAGONISTS AND SEROTONIN UPTAKE INHIBITORS | ABBOTT LABORATORIES (US) | 1995-04-05 | — | — | EP | disclosed |
| US-5288749-A | Treating central nervous system or cardiovascular disorders | ABBOTT LABORATORIES (US) | 1994-02-22 | — | — | US | disclosed |
| WO-1993012754-A2 | TERTIARY AND SECONDARY AMINES AS ALPHA-2 ANTAGONISTS AND SEROTONIN UPTAKE INHIBITORS | ABBOTT LABORATORIES (US) | 1993-07-08 | — | — | WO | disclosed |
| US-4372970-A | NONPHYTOTOXIC, PHOTOSTABLE | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 1983-02-08 | — | — | US | disclosed |
| WO-1981001408-A1 | SUBSTITUTED ACETIC ACID ESTERS AS PESTICIDES | SOREX LTD (GB) | 1981-05-28 | — | — | WO | disclosed |
| EP-0029360-A1 | Pesticidal compounds, compositions containing them and methods of killing arthropods using them | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1981-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767305-B2 | Advantageous benzofuran compositions for mental disorders or enhancement | BDNF, CREBBP, ELF3 | GAA 1540/4885MEN1 2215/4885ALDH1A1 990/4885 |
| US-12404257-B2 | Advantageous benzofuran compositions for mental disorders or enhancement | BDNF, CREBBP, ELF3 | GAA 1540/4885MEN1 2215/4885ALDH1A1 990/4885 |
| US-20240083864-A1 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | BDNF, CREBBP, ELF3 | GAA 1540/4885MEN1 2215/4885ALDH1A1 990/4885 |
| US-20030083347-A1 | Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same | ADRB3, DRD3, CHRM3 | GAA 3857/4885MEN1 1970/4885ALDH1A1 1285/4885 |
| US-12344591-B2 | Advantageous benzofuran compositions for mental disorders or enhancement | BDNF, CREBBP, ELF3 | GAA 1540/4885MEN1 2215/4885ALDH1A1 990/4885 |
| US-12365661-B2 | Advantageous benzofuran compositions for mental disorders or enhancement | BDNF, CREBBP, ELF3 | GAA 1540/4885MEN1 2215/4885ALDH1A1 990/4885 |
| US-20250019357-A1 | BENZOFURAN SALT MORPHIC FORMS AND MIXTURES FOR THE TREATMENT OF MENTAL DISORDERS OR MENTAL ENHANCEMENT | ELF3, BDNF, ETV6 | GAA 2334/4885MEN1 908/4885ALDH1A1 1696/4885 |
| US-20250188049-A1 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | BDNF, CREBBP, ELF3 | GAA 1540/4885MEN1 2215/4885ALDH1A1 990/4885 |
| US-20250034102-A1 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | BDNF, CREBBP, ELF3 | GAA 1540/4885MEN1 2215/4885ALDH1A1 990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.